Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by saltajaon Nov 25, 2015 5:49pm
281 Views
Post# 24326037

RE:RE:How did 4050 get ODD if 25% adults have metabolic syndrome?

RE:RE:How did 4050 get ODD if 25% adults have metabolic syndrome?FD,
It is true that 4050 has ODD for IPF only so far. Alfred's question, which is the same one I posted a couple days ago, is why does Prometic call MS+T2D an orphan indication. See slide 24 of the July presentation still available on the website for where MS+T2D is listed as orphan. These can't be orphan indications. Any insight on that? 

BTW, thanks for all your great analysis.
Bullboard Posts